-
- 抗原
- Colorectal Carcinoma/CD3
- 适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- 非结合性
- 应用范围
- Enzyme Immunoassay (EIA), Flow Cytometry (FACS)
- 交叉反应 （详细）
- Species reactivity (tested):Human.
- 产品特性
- Synonyms: CRC/CD3, Hybrid bispecific antibody
- 纯化方法
- Affinity Chromatography on Protein G.
- 克隆位点
- BS-1
- 亚型
- IgG1/IgG2a
-
-
- 应用备注
-
ELISA.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. - 限制
- 仅限研究用
-
- 溶解方式
- Restore with Double distillated water to adjust the final concentration to 1.0 mg/mL.
- 缓冲液
- 0.01 M PBS, pH 7.0 without preservatives
- 储存液
- Without preservative
- 储存条件
- -20 °C
- 储存方法
-
Store the antibody at -20 °C. After reconstitution, aliquot and store at -20 °C.
Shelf life: one year from despatch. - 有效期
- 12 months
-
- 抗原
- Colorectal Carcinoma/CD3
- 背景
- Colorectal carcinoma is the cancer developed in the colon or rectum of the digestive system. In developed countries, it is the most common cancer in aging population. Genetic deposition and a less active life style contribute to the development of the cancer. Molecular pathological study showed that altered Wnt-APC-β-catenim signaling pathway, mutated p53, and deactivated TGF-β and DCC (Deleted in Colon Cancer) are involved with the pathogenesis. The cancer is currently screened with a fecal occult blood test in people over 50 years old and the malignancy is confirmed by tumor biopsy. The search for specific biomarker for non-invasive test is still ongoing. CD3 exists on the cell surface of all T-cell types. It is used for differentiating Tcells from other leukocytes such as B cells and natural killer cells. CD3 is the accessory molecule in the T cell receptorcomplex. In the presence of CD3 and ζ- chain, T-cell receptor binds to antigen presented by MHC and transfers signal for T-cell activation. The hybrid bi-specific antibody binds to CD3 and colorectal carcinoma related antigen at its two different Fabs. Theoretically, the bi-specific antibody brings the target cancer antigen near Tcells and could enhance T-cell mediated immunity to cancer. However, if the binding to CD3 disrupts the CD3's accessory function, T-cell immunity suppression could be resulted.Synonyms: CRC/CD3, Hybrid bispecific antibody
-
You are here:
